CORPORATE DISCLOSURE STATEMENT Sample Clauses

CORPORATE DISCLOSURE STATEMENT. Distributor is a wholly-owned direct subsidiary of Priority Healthcare Corporation (“PHC”), which is a diversified health care company that among other things owns or operates specialty and infusion pharmacies, wholesale distribution facilities, and a group purchasing organization. PHC is wholly-owned by CuraScript, Inc. (“CuraScript”), which is a diversified healthcare company principally focused on specialty pharmacy, biotech distribution, and related services. CuraScript is wholly-owned by Express Scripts, Inc. (“Express Scripts”), which is a publicly traded diversified health care company that, in addition to owning CuraScript, owns or operates several other businesses, including (but not limited to) one of the nation’s largest pharmacy benefit managers and several mail service pharmacies. More information on Express Scripts can be found in its public filings with the Securities and Exchange Commission. Each of the Express Scripts, CuraScript, and PHC businesses already may have (or may develop in the future) relationships with vendors, including vendors that contract with Distributor to provide goods and services to Distributor’s customers. These relationships may involve discounted purchasing relationships, rebate-type arrangements, and payments for services. If Company desires additional information regarding any of the information that already has been provided in this Corporate Disclosure Statement, Distributor will provide Company with such additional information upon request.
Sample 1Sample 2
AutoNDA by SimpleDocs
CORPORATE DISCLOSURE STATEMENT. CuraScript is a diversified healthcare company principally focused on specialty pharmacy, biotech distribution, and related services. CuraScript wholly owns Priority Healthcare Corporation (“PHC”), a company that owns or operates specialty and infusion pharmacies, wholesale distribution facilities, and a group purchasing organization. CuraScript is wholly-owned by Express Scripts, Inc. (“Express Scripts”), which is a publicly traded diversified health care company that, in addition to owning CuraScript, owns or operates several other businesses, including (but not limited to) one of the nation’s largest pharmacy benefit managers and several mail service pharmacies. More information on Express Scripts can be found in its public filings with the Securities and Exchange Commission. Each of the Express Scripts, CuraScript, and PHC businesses already may have (or may develop in the future) relationships with vendors, including vendors that contract with CuraScript to provide goods and services to CuraScript’s customers. These relationships may involve discounted purchasing relationships, rebate-type arrangements, and payments for services. If Company desires additional information regarding any of the information that already has been provided in this Corporate Disclosure Statement, CuraScript will provide Company with such additional information upon request.
Sample 1
CORPORATE DISCLOSURE STATEMENT. Defendants-Appellants submit this list, which includes the trial judge, and all attorneys, persons, associations of persons, firms, partnerships or corporations that have an interest in the outcome of this review:
Sample 1
CORPORATE DISCLOSURE STATEMENT. (Continued)
Sample 1
CORPORATE DISCLOSURE STATEMENT. (Continued) UNOPPOSED MOTION FOR VOLUNTARY DISMISSAL Appellant La-Z-Boy Incorporated moves this Court for a voluntary dismissal of its appeal, pursuant to Rule 42(b) of the Federal Rules of Appellate Procedure and 11th Circuit Rule 42-1(a). Counsel for Plaintiff-Appellee does not oppose this motion. Defendant-Appellant and Plaintiff-Appellee have reached an agreement to settle this matter. Each party will bear its respective costs and attorneys’ fees incurred in connection with this appeal. No costs will be imposed, and no attorneys’ fees will be assessed against either Party.
Sample 1
CORPORATE DISCLOSURE STATEMENT. (Continued) Respectfully submitted, Xxxxx X. Xxxxxxxxx Xxxxxx X. Xxxxxxxx Xxxx X. XxXxxxx Xxxxxx X. Xxxx Xxxxxx Xxxxxxxxx Xxxxxxx, P.A. Xxxxxxxxx Xxxxxxx, P.A. 000 Xxxx Xxx Xxxx Xxxx., Xxxxx 0000 Xxxxx Xxxxx Xxxxxx, Xxxxx 0000 Xxxx Xxxxxxxxxx, Xxxxxxx 00000 000 Xxxxxxxxx Xxxxxx Xxxxxx Telephone: 000.000.0000 Xxxxx, Xxxxxxx 00000 Facsimile: 000.000.0000 Telephone: 000.000.0000 Facsimile: 305.579.0717 By: /s/ Xxxxxx X. Xxxx Xxxxxx Xxxxxx X. Xxxx Samole Counsel for Defendants-Appellants
Sample 1
CORPORATE DISCLOSURE STATEMENT. (Continued) Xxxxxxxxxxx, Xxxxxxxxx 00000 Telephone: (000) 000-0000 Telephone: (000) 000-0000 Email: xxxxxxxx@xxxxxxxxxxx.xxx Facsimile: (000) 000-0000 Email: xxxxxxxx@xxxxxxxxxxx.xxx Email: xxxxxx@xxxxxxxxxxxx.xxx Email: xxxxxxx@xxxxxxxxxxxx.xxx Email: xxxxxxxx@xxxxxxxxxxxx.xxx Email: xxxxxxxxxx@xxxxxxxxxxxx.xxx Email: xxxxxxx@xxxxxxxxxxxx.xxx Email: xxxxxx@xxxxxxxxxxxx.xxx Email: Xxxxxx_Xxxxxx_XX@xxxxxxxxxxxx.xxx Xxxxxx X. Xxxxxx, Esq. Xxxxxxx X. Xxxxxx, Esq. Robins Xxxxxx L.L.P. 000 Xxxxxxxxx Xxxxxx, Xxxxx 0000 Xxx Xxxx, Xxx Xxxx 00000-0000 Telephone: (000) 000-0000 Facsimile: (000) 000-0000 Email: xxxxxxx@xxxxxxxxxxxx.xxx Email: xxxxx@xxxxxxxxxxxx.xxx Email: xxxxxxx@xxxxxxxxxxxx.xxx /s/ Xxxxxx X. Xxxx Xxxxxx Xxxxxx X. Xxxx Samole EXHIBIT C FORM OF JOINDER JOINDER I HAVE READ AND UNDERSTAND PARAGRAPH 7 OF THE CONFIDENTIAL SETTLEMENT AGREEMENT DATED DECEMBER 2017, AND I IRREVOCABLY AGREE TO BE BOUND BY ALL OF THE STIPULATIONS AND REQUIREMENTS OF PARAGRAPH 7 OF THE CONFIDENTIAL SETTLEMENT AGREEMENT AS THOUGH I WAS A PARTY THERETO, INCLUDING THE REQUIREMENT NOT TO DISCLOSE THE CONFIDENTIAL INFORMATION TO THIRD PARTIES EXCEPT AS PERMITTED THEREIN. Signature Print Name Signed Above Date EXHIBIT D FORM OF CERTIFICATION CERTIFICATION I HEREBY CERTIFY, that from the Effective Date to the date of Closing (as defined in the Confidential Settlement Agreement), the Parties and persons bound by the confidentiality provisions of this Paragraph 7 have not violated Paragraph 7 of the Confidentiality Agreement.
Sample 1
AutoNDA by SimpleDocs
CORPORATE DISCLOSURE STATEMENT. Not applicable.
Sample 1

Related to CORPORATE DISCLOSURE STATEMENT

  • Risk Disclosure Statement Counterparty represents and warrants that it has received, read and understands the OTC Options Risk Disclosure Statement provided by Dealer and a copy of the most recent disclosure pamphlet prepared by The Options Clearing Corporation entitled “Characteristics and Risks of Standardized Options”.

  • Disclosure Statement A disclosure statement of the Property signed and dated by the Seller;

  • Accurate Disclosure Neither the Registration Statement nor any amendment thereto, at its effective time, on the date hereof, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. At the Applicable Time and any Date of Delivery, none of (A) the General Disclosure Package and (B) any individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto, as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through BofA expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in the first paragraph under the heading “Underwriting–Commissions and Discounts,” the information in the second, third and fourth paragraphs under the heading “Underwriting–Price Stabilization, Short Positions and Penalty Bids” and the information under the heading “Underwriting–Electronic Distribution”, in each case contained in the Prospectus (collectively, the “Underwriter Information”).

  • Complete Disclosure No Loan Document contains any untrue statement of a material fact, nor fails to disclose any material fact necessary to make the statements contained therein not materially misleading. There is no fact or circumstance that any Obligor has failed to disclose to Agent in writing that could reasonably be expected to have a Material Adverse Effect.

  • Accurate and Complete Disclosure The information, reports, Financial Statements, exhibits and schedules furnished in writing by or on behalf of each Seller Party to Buyer in connection with the negotiation, preparation or delivery of this Agreement or performance hereof and the other Program Documents or included herein or therein or delivered pursuant hereto or thereto, when taken as a whole, do not contain any untrue statement of material fact or omit to state any material fact necessary to make the statements herein or therein, in light of the circumstances under which they were made, not misleading. All written information furnished after the date hereof by or on behalf of each Seller Party to Buyer in connection with this Agreement and the other Program Documents and the transactions contemplated hereby and thereby including without limitation, the information set forth in the related Mortgage Loan Schedule, will be true, complete and accurate in every material respect, or (in the case of projections) based on reasonable estimates, on the date as of which such information is stated or certified. There is no fact known to Seller, after due inquiry, that could reasonably be expected to have a Material Adverse Effect that has not been disclosed herein, in the other Program Documents or in a report, financial statement, exhibit, schedule, disclosure letter or other writing furnished to Buyer for use in connection with the transactions contemplated hereby or thereby.

  • True and Complete Disclosure The information, reports, financial statements, exhibits and schedules furnished in writing by or on behalf of the Borrower to the Lender in connection with the negotiation, preparation or delivery of this Loan Agreement and the other Loan Documents or included herein or therein or delivered pursuant hereto or thereto, when taken as a whole, do not contain any untrue statement of material fact or omit to state any material fact necessary to make the statements herein or therein, in light of the circumstances under which they were made, not misleading. All written information furnished after the date hereof by or on behalf of the Borrower to the Lender in connection with this Loan Agreement and the other Loan Documents and the transactions contemplated hereby and thereby will be true, complete and accurate in every material respect, or (in the case of projections) based on reasonable estimates, on the date as of which such information is stated or certified. There is no fact known to a Responsible Officer that, after due inquiry, could reasonably be expected to have a Material Adverse Effect that has not been disclosed herein, in the other Loan Documents or in a report, financial statement, exhibit, schedule, disclosure letter or other writing furnished to the Lender for use in connection with the transactions contemplated hereby or thereby.

  • of the Disclosure Schedules (a) to the Company’s Knowledge, the Company owns or possesses sufficient legal rights to all Company Intellectual Property without any conflicts with, or infringement of, the rights of others, and no product or service marketed or sold (or proposed to be marketed or sold) by the Company violates or will violate any license or infringes or will infringe any intellectual property rights of any other party; (b) other than with respect to commercially available software products under standard end-user object code license agreements or standard license agreements for open source software, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Intellectual Property, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the Patents, Trademarks, Copyrights, Trade Secrets, licenses, information, proprietary rights and processes of any other Person; (c) no claim has been asserted or, to the Company’s Knowledge, threatened against the Company involving any Intellectual Property; (d) to the Company’s Knowledge, it will not be necessary to use any inventions of any of its employees or consultants made prior to or outside the scope of their employment by the Company; (e) each employee and consultant has (i) assigned to the Company all Intellectual Property rights he or she owns that are related to the business of the Company and (ii) executed an agreement with the Company acknowledging the Company’s exclusive ownership of all Intellectual Property invented, created or developed by such employee or independent contractor within the scope of his or her employment or engagement with the Company; (f) the Company does not utilize any open source software in a manner that requires the Company to disclose, make available, or offer or deliver any portion of the source code of any proprietary Company software or component thereof to any third party.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!